Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

Novartis Pharmaceuticals2,136 enrolled

Overview

The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

2,136

Conditions

Pneumonia

Interventions

TifacoginDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of community-acquired pneumonia supported by additional clinical, radiological, and microbiological evidence * Pneumonia of sufficient severity to require ICU admission and management Exclusion Criteria: * Pregnancy * Weight over 150 kg * Patients at increased risk of bleeding * Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa * Treatment with heparin or anticipated need for heparin

Locations (150)

Outcomes

Primary Outcomes

Compare the effect of tifacogin vs placebo administration.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Mobile, Alabama, United States

Unnamed facility

Loma Linda, California, United States

Unnamed facility

Los Angeles, California, United States

Unnamed facility

Orange, California, United States

Unnamed facility

Sacramento, California, United States

Unnamed facility

San Diego, California, United States

Unnamed facility

San Jose, California, United States

Unnamed facility

Denver, Colorado, United States

Unnamed facility

Farmington, Connecticut, United States

Unnamed facility

New Haven, Connecticut, United States

...and 140 more locations